Royal Bank of Canada Reduces Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Royal Bank of Canada lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,272,531 shares of the medical research company's stock after selling 55,713 shares during the period. Royal Bank of Canada owned about 0.86% of Thermo Fisher Scientific worth $1,702,469,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Capital Investment Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 15.4% during the fourth quarter. Capital Investment Advisors LLC now owns 1,335 shares of the medical research company's stock worth $695,000 after buying an additional 178 shares in the last quarter. SeaCrest Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 26.7% in the 4th quarter. SeaCrest Wealth Management LLC now owns 1,743 shares of the medical research company's stock valued at $907,000 after acquiring an additional 367 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. grew its position in shares of Thermo Fisher Scientific by 74.7% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 166 shares of the medical research company's stock valued at $86,000 after purchasing an additional 71 shares in the last quarter. Pinnacle Bancorp Inc. grew its position in shares of Thermo Fisher Scientific by 18.1% in the fourth quarter. Pinnacle Bancorp Inc. now owns 866 shares of the medical research company's stock valued at $451,000 after purchasing an additional 133 shares in the last quarter. Finally, HCR Wealth Advisors grew its position in shares of Thermo Fisher Scientific by 0.7% in the fourth quarter. HCR Wealth Advisors now owns 7,499 shares of the medical research company's stock valued at $3,902,000 after purchasing an additional 54 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TMO shares. UBS Group dropped their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Evercore ISI dropped their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Scotiabank dropped their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Finally, Royal Bank of Canada cut their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $607.43.

Thermo Fisher Scientific Stock Up 0.4%

Shares of NYSE TMO traded up $1.69 during mid-day trading on Monday, hitting $413.75. The company had a trading volume of 1,664,931 shares, compared to its average volume of 1,840,182. The company has a market capitalization of $156.19 billion, a PE ratio of 25.03, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88. The business's 50-day simple moving average is $453.88 and its 200 day simple moving average is $509.89.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company's revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the firm earned $5.11 earnings per share. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a $0.43 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,075 shares of company stock worth $7,305,942. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.